Most systematic reviews of adverse effects did not include unpublished data

Journal of Clinical Epidemiology

Volumn 77, Issue , 2016, Pages 125-133

  Golder, Su ^a   Loke, Yoon K ^b   Wright, Kath ^a   Sterrantino, Carmelo ^c  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

Adverse effects; Gray literature; Information retrieval; Systematic review; Trial registry; Unpublished data

Indexed keywords

CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ADVERSE DRUG REACTION; ADVERSE OUTCOME; ARTICLE; BIBLIOGRAPHIC DATABASE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; COCHRANE LIBRARY; DATA ANALYSIS; DATA EXTRACTION; DISEASE REGISTRY; EMBASE; GASTROINTESTINAL SYMPTOM; HUMAN; MEDLINE; PEER REVIEW; PRIORITY JOURNAL; PUBLICATION; SYSTEMATIC REVIEW; THROMBOSIS; LITERATURE; PUBLISHING; STATISTICS AND NUMERICAL DATA;

DATABASES, BIBLIOGRAPHIC; HUMANS; PUBLISHING; REVIEW LITERATURE AS TOPIC;

EID: 84977599952     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2016.05.003     Document Type: Article

References (41)

1. [1] Chou, R., Aronsonb, N., Atkinsc, D., Ismailad, A.S., Santaguidad, P., Smith, D.H., AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care Program. J Clin Epidemiol 63 (2010), 502–512.
2. [2] Hodkinson, A., Kirkham, J.J., Tudur-Smith, C., Gamble, C., Reporting of harms data in RCTs: a systematic review of empirical assessments against the CONSORT harms extension. BMJ Open, 3(9), 2013, e003436.
3. [3] Anderson, P.A., Hart, R.A., Adverse events recording and reporting in clinical trials of cervical total disk replacement. Instr Course Lect 63 (2014), 287–296.
4. [4] Haidich, A.B., Birtsou, C., Dardavessis, T., Tirodimos, I., Arvanitidou, M., The quality of safety reporting in trials is still suboptimal: survey of major general medical journals. J Clin Epidemiol 64 (2011), 124–135.
5. [5] Hussein, H.M., Baybutt, T.R., Zhou, J.Y., Divani, A.A., Qureshi, A.I., The quality of adverse event reporting in drug-related hemorrhagic stroke trials from the stroke trials registry. Stroke, 38, 2007, 543.
6. [6] Liebeskind, D.S., Kidwell, C.S., Sayre, J.W., Saver, J.L., Evidence of publication bias in reporting acute stroke clinical trials. Neurology 67 (2006), 973–979.
7. [7] Pezo, R.C., Seruga, B., Krzyzanowska, M.K., Bedard, P., Quality of safety reporting in oncology-randomized controlled trials (RCTs). J Clin Oncol, 29, 2011 e13037.
8. [8] Pitrou, I., Boutron, I., Ahmad, N., Ravaud, P., Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 169 (2009), 1756–1761.
9. [9] Scharf, O., Colevas, A.D., Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol 24 (2006), 3933–3938.
10. [10] Golder, S., Loke, Y.K., Bland, M., Unpublished data can be of value in systematic reviews of adverse effects: methodological overview. J Clin Epidemiol 63 (2010), 1071–1081.
11. [11] Hart, B., Lundh, A., Bero, L., Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ 344 (2012), 1–11.
12. [12] Higgins, J., Green, S., (eds.) Cochrane Handbook for Systematic Reviews of Interventions, 2011, The Cochrane Collaboration Version 5.1.0 [updated March 2011]. Available at www.cochrane-handbook.org Accessed June 15, 2016.
13. [13] Centre for Reviews & Dissemination (CRD). Undertaking systematic reviews of effectiveness: CRD guidance for those carrying out or commissioning reviews. 2nd ed., 2008, Centre for Reviews & Dissemination (CRD), York.
14. [14] Institute of Medicine. Finding What Works in Health Care: Standards for Systematic Reviews. 2011, National Academies Press, Washington.
15. [15] Golder, S., Loke, Y.K., Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies?. Br J Clin Pharmacol 66 (2008), 767–773.
16. [16] van Driel, M.L., De Sutter, A., De Maeseneer, J., Christiaens, T., Searching for unpublished trials in Cochrane reviews may not be worth the effort. J Clin Epidemiol 62 (2009), 838–844.
17. [17] Carragee, E.J., Hurwitz, E.L., Weiner, B.K., A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 11 (2011), 471–491.
18. [18] Hartung, D.M., Zarin, D.A., Guise, J.M., McDonagh, M., Paynter, R., Helfand, M., Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications. Ann Intern Med 160 (2014), 477–483.
19. [19] Hughes, S., Cohen, D., Jaggi, R., Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study. BMJ Open, 4(7), 2014, e005535.
20. [20] Maund, E., Tendal, B., Hróbjartsson, A., Jørgensen, K.J., Lundh, A., Schroll, J., et al. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. BMJ 348 (2014), 1–11.
21. [21] Rodgers, M.A., Brown, J.V., Heirs, M.K., Higgins, J.P., Mannion, R.J., Simmonds, M.C., et al. Reporting of industry funded study outcome data: comparison of confidential and published data on the safety and effectiveness of rhBMP-2 for spinal fusion. BMJ, 346, 2013, f3981.
22. [22] Jefferson, T., Doshi, P., Thompson, M., Heneghan, C., Ensuring safe and effective drugs: who can do what it takes?. BMJ, 342, 2011, c7258.
23. [23] Le Noury, J., Nardo, J.M., Healy, D., Jureidini, J., Raven, M., Tufanaru, C., et al. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ, 351, 2015, h4320.
24. [24] Pranić, S., Marušić, A., Changes to registration elements and results in a cohort of Clinicaltrials.gov trials were not reflected in published articles. J Clin Epidemiol 70 (2016), 26–37.
25. [25] Tang, E., Ravaud, P., Riveros, C., Perrodeau, E., Dechartres, A., Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles. BMC Med, 13, 2015, 189.
26. [26] Golder, S., McIntosh, H.M., Loke, Y., Identifying systematic reviews of the adverse effects of health care interventions. BMC Med Res Methodol, 8, 2006, 22.
27. [27] Golder, S., Loke, Y.K., Zorzela, L., Some improvements are apparent in identifying adverse effects in systematic reviews from 1994 to 2011. J Clin Epidemiol 66 (2013), 253–260.
28. [28] Golder, S., Loke, Y.K., Zorzela, L., Comparison of search strategies in systematic reviews of adverse effects to other systematic reviews. Health Info Libr J 31 (2014), 92–105.
29. [29] Eyding, D.L., Lelgemann, M., Grouven, U., Harter, M., Kromp, M., Kaiser, T., et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ, 341, 2010, 816.
30. [30] Gupta, S., Agomelatine-Is it another reboxetine? Another case of publication bias. Psychiatr Bull, 38, 2014, 88.
31. [31] Mayo-Wilson, E., Doshi, P., Dickersin, K., Are manufacturers sharing data as promised?. BMJ, 351, 2015, h4169.
32. [32] Doshi, P., Jefferson, T., Open data 5 years on: a case series of 12 freedom of information requests for regulatory data to the European Medicines Agency. Trials, 17(1), 2016, 78.
33. [33] Doshi, P., Jefferson, T., Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. BMJ Open, 3(2), 2013.
34. [34] Doshi, P., Jefferson, T., Del Mar, C., The imperative to share clinical study reports: recommendations from the Tamiflu experience. PLoS Med, 9(4), 2012, e1001201.
35. [35] Wieseler, B., Wolfram, N., McGauran, N., Kerekes, M.F., Vervolgyi, V., Kohlepp, P., et al. Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data. PloS Med, 10(10), 2013, e1001526.
36. [36] Wieseler, B., Kerekes, M., Vervoelgyi, V., McGauran, N., Kaiser, T., Impact of document. Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications. BMJ, 344, 2012, d8141.
37. [37] Wieseler, B., McGauran, N., Kerekes, M.F., Kaiser, T., Access to regulatory data from the European Medicines Agency: the times they are a-changing. Syst Rev, 1, 2012, 50.
38. [38] Anderson, M.L., Karen Chiswell, K., Peterson, E.D., Tasneem, A., Topping, J., Califf, R.M., Compliance with results reporting at ClinicalTrials.gov. N Engl J Med 372 (2015), 1031–1039.
39. [39] Prayle, A.P., Hurley, M.N., Smyth, A.R., Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. BMJ, 344, 2012, d7373.
40. [40] Law, M.R., Kawasumi, Y., Morgan, S.G., Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on ClinicalTrials.gov. Health Aff (millwood) 30 (2011), 2338–2345.
41. [41] Riveros, C., Dechartres, A., Perrodeau, E., Haneef, R., Boutron, I., Ravaud, P., Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals. PloS Med, 10(12), 2013, e1001566.